Keenova Therapeutics plc - Company Profile

All the sales intelligence you need on Keenova Therapeutics plc in one solution.

Save hours of research time with a comprehensive
Sales Intelligence Solution.
Understand how Keenova Therapeutics plc fits into your total
addressable market and Ideal Customer Profile.
Gain competitive edge with triggers that tell you
when and how to engage with Keenova Therapeutics plc.

Keenova Therapeutics plc: Premium Databases

Contact the team or request a demo to find out how our data can drive your business forward

Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.

Headline	Published	Journalists
Showing 3 of 40+ results.
Deserunt mollit sunt Lorem laborum do id aliqua dolore	26 Jun 2019	Lorem
Mallinckrodt’s CPP-1X/sulindac for FAP has positive Phase III prospects due to data, trial design but efficacy/safety clarity still needed, experts say	17 Oct 2018	Reynald Castaneda
Alkermes’ ALKS-5461 likely requires additional Phase III MDD trial for regulatory approvals based on past mixed results – experts	02 Dec 2016	Hamish McDougall
Sucampo’s eflornithine/Clinoril combo faces tough Phase III futility bar with uncertainty on required FAP events occurring - experts	17 Oct 2016	Manasi Vaidya

Delivers exclusive investigative journalist content including breaking news and analysis ahead of market-moving events.

Drug Insights:

Forward-looking, nuanced, qualitative asset analysis on development, approval & market/reimbursement potential
Material intelligence on competitors, including breaking news
Insight on companies’ business development needs and strategies

Outsourcing Insights:

Insight on companies’ CRO and business development needs, strategies and relationships

Remove risk and uncertainty

Gain a competitive edge

Secure actionable leads

Gain a 360-degree view of Keenova Therapeutics plc and make more informed decisions for your business

Still looking?

Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.

Explorer

Access more premium companies when you subscribe to Explorer